[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617805":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":10,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":31,"acronym":10,"eligibilityCriteria":32,"healthyVolunteers":33,"sex":34,"minAge":35,"maxAge":10,"enrollmentInfo":36,"targetDuration":10,"studyType":39,"phases":10,"briefSummary":40,"conditions":41,"keywords":47,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":10},{"fullName":5,"class":6},"PeriPharm","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Caregiver of child with atopic dermatitis",null,"Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis",[13],"Other: No Intervention: Observational Cohort",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"No Intervention: Observational Cohort","No specific intervention is assess in this study. Observational cohort.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Jean Lachaine, Ph. D.","CONTACT","514-731-8207","jean.lachaine@peripharm.com",{"type":26,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100617805","real-world-study-on-the-impact-of-atopic-dermatitis-from-a-caregiver-perspective-100617805",false,"NCT07323394","Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective","Inclusion Criteria:\n\n1. Aged ≥18 years;\n2. Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis;\n3. Able to read and understand French or English;\n4. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Caregivers whose child has been diagnosed with severe atopic dermatitis ;\n2. Caregivers whose child is currently treated with oral or topical Janus Kinase Inhibitor);\n3. Caregivers whose child is currently participating in a clinical trial for atopic dermatitis;\n4. Other parent or caregiver within the household of the child with atopic dermatitis.",true,"ALL","18 Years",{"count":37,"type":38},100,"ESTIMATED","OBSERVATIONAL","This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.",[42,43,44,45,46],"Atopic Dermatitis","Eczema Atopic Dermatitis","Eczema","Caregiver","Burden",[48,49,50],"atopic dermatitis","quality of life","real-world","NOT_YET_RECRUITING","2026-01-22",{"date":54,"type":55},"2026-01-23","ACTUAL",{"date":57,"type":38},"2026-01",{"date":59,"type":38},"2026-07",{"name":5,"class":6}]